+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cancer Immunotherapy Market - Global Forecast 2026-2032- Product Image
Cancer Immunotherapy Market - Global Forecast 2026-2032- Product Image
Sale

Cancer Immunotherapy Market - Global Forecast 2026-2032

  • Report

  • 193 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6010622
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cancer Immunotherapy Market is projected to reach USD 162.78 Billion in 2026. It is expected to continue growing at a CAGR of 10.74%, reaching USD 293.07 Billion by 2032.

Cancer immunotherapy has moved from a specialized oncology approach to a core pillar of cancer treatment, reshaping standards of care across hematologic malignancies and solid tumors. Immune checkpoint inhibitors, CAR-T cell therapies, bispecific antibodies, antibody-drug conjugate combinations, therapeutic cancer vaccines, oncolytic viruses, cytokine-based therapies, and tumor-infiltrating lymphocyte therapies are now central to clinical and commercial strategies.

The growth imperative is supported by verified epidemiology. The International Agency for Research on Cancer reported approximately 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022 and projects more than 35 million new cancer cases by 2050. This rising burden is accelerating demand for durable, biomarker-guided, and combination-based immuno-oncology treatments that can improve survival while supporting precision medicine adoption.

Transformative Shifts in the Immunotherapy Landscape

The cancer immunotherapy landscape is being transformed by a shift from single-agent therapies toward rational combinations, earlier-line treatment, and biomarker-selected patient populations. PD-1, PD-L1, and CTLA-4 inhibitors established immuno-oncology as a mainstream treatment category, while next-generation modalities are addressing resistance, relapse, and tumor microenvironment suppression.

Manufacturing and delivery models are also changing. Autologous cell therapy capacity, allogeneic platforms, decentralized manufacturing, vein-to-vein logistics, and real-world evidence programs are becoming competitive differentiators. At the same time, payers and health technology assessment agencies are applying stricter scrutiny to durability, quality-adjusted survival, safety management, and total cost of care.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative value across cancer immunotherapy discovery, development, and commercialization. AI-enabled target discovery, antigen prediction, neoantigen prioritization, spatial biology analysis, digital pathology, and multimodal biomarker modeling are helping researchers identify patients most likely to respond and design more precise treatment strategies.

In clinical operations, AI supports trial matching, eligibility screening, site selection, adverse event signal detection, and real-world evidence generation. The most immediate value is not replacing clinical judgment but improving decision speed, reducing failed enrollment, and strengthening companion diagnostic strategies. Leaders that combine AI governance, high-quality datasets, and regulatory-grade validation are positioned to accelerate immuno-oncology innovation responsibly.

Key Regional Insights

North America remains a global center for cancer immunotherapy innovation due to dense clinical trial networks, advanced academic cancer centers, FDA regulatory pathways, and strong biopharma financing. The United States anchors early adoption of checkpoint inhibitors, cell therapies, bispecific antibodies, and biomarker testing, while Canada contributes through public health systems, oncology research networks, and precision medicine initiatives supported by evidence-based reimbursement review.

Europe is shaped by EMA oversight, national reimbursement systems, and health technology assessment requirements that prioritize evidence quality, cost-effectiveness, and real-world outcomes. Asia-Pacific is expanding as China, Japan, South Korea, India, and Australia increase clinical research output, biologics manufacturing, regulatory modernization, and oncology infrastructure. Latin America, led by Brazil and Mexico, is improving specialty access and clinical trial participation but continues to face affordability, pathology, and molecular diagnostic capacity constraints. The Middle East, particularly GCC markets, is investing in tertiary cancer centers, genomic medicine, and specialty procurement, while Africa’s opportunity depends on strengthening pathology, cold-chain logistics, oncology workforce capacity, pharmacovigilance, and equitable access programs.

Key Group Insights

The G7 continues to drive premium immuno-oncology innovation through mature regulatory systems, high clinical trial density, specialized cancer centers, and established reimbursement pathways, making it a critical launch environment for checkpoint inhibitors, cell therapies, bispecific antibodies, and companion diagnostics. NATO markets overlap with many advanced oncology systems and also highlight the importance of secure pharmaceutical supply chains, data protection, cyber-resilient clinical infrastructure, and resilient biologics manufacturing.

The European Union benefits from centralized EMA authorization and a growing emphasis on joint health technology assessment, which can improve market consistency while maintaining pressure on comparative effectiveness and value demonstration. BRICS countries offer population scale, expanding clinical research participation, increasing domestic biologics capacity, and rising demand for oncology access, though availability varies significantly by reimbursement, diagnostics, and infrastructure. ASEAN markets are advancing unevenly, with Singapore, Thailand, and Malaysia showing stronger specialty oncology capabilities, while broader regional adoption depends on workforce development, pathology access, and affordability. GCC countries are using national transformation agendas to expand precision oncology, specialty procurement, genomic medicine, and regional cancer care hubs.

Key Country Insights

The United States leads cancer immunotherapy commercialization through FDA approvals, advanced biomarker testing, broad clinical trial access, academic cancer networks, and strong life sciences financing. Canada emphasizes evidence-based adoption through provincial reimbursement systems and pan-Canadian oncology assessment processes. Mexico and Brazil represent important Latin American access markets, with progress tied to public-private oncology capacity, specialty distribution, clinical research participation, and diagnostic expansion.

In Europe, the United Kingdom combines NHS real-world evidence capabilities with strong oncology research, while Germany and France are central to reimbursement evaluation, clinical adoption, and biomarker testing infrastructure. Italy and Spain contribute robust oncology networks and expanding access to precision medicine, while Russia maintains domestic oncology demand despite geopolitical, regulatory, and supply access complexity. In Asia-Pacific, China has become a major immuno-oncology development engine supported by large clinical trial activity and domestic biologics capacity; India offers large patient populations, expanding biosimilar capabilities, and rising oncology infrastructure; Japan supports high-quality regulatory and clinical infrastructure with strong adoption of innovative oncology therapies; South Korea is strong in biologics, digital health, and cell therapy innovation; and Australia remains a preferred clinical trial destination with globally respected cancer centers and strong translational research capabilities.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize biomarker-led development, combination strategies with clear mechanistic rationale, and trial designs that demonstrate durable benefit in defined patient segments. Strong companion diagnostic planning, inclusive enrollment, decentralized trial capabilities, and real-world evidence generation are essential to improve clinical utility, regulatory confidence, and payer acceptance.

Manufacturers should strengthen cell and gene therapy supply chains, invest in scalable manufacturing, and build capabilities for adverse event management, including cytokine release syndrome and immune-related toxicities. Commercial teams should prepare access dossiers that address survival, quality of life, durability, site-of-care economics, and long-term value. Partnerships with academic centers, diagnostic developers, AI platforms, contract manufacturers, and regional health systems can accelerate access, operational resilience, and differentiation.

Research Methodology

The executive summary is developed using a secondary research approach grounded in publicly available and authoritative sources, including cancer epidemiology from international health agencies, regulatory information from major agencies, clinical trial registries, peer-reviewed oncology literature, health technology assessment practices, oncology guideline updates, and immuno-oncology development activity.

The methodology emphasizes triangulation across epidemiological data, therapeutic approvals, clinical development patterns, regional healthcare infrastructure, reimbursement dynamics, manufacturing considerations, diagnostics adoption, and technology signals. Insights are synthesized to support strategic decision-making for executives, investors, manufacturers, diagnostics developers, healthcare providers, and policy stakeholders operating across the cancer immunotherapy value chain.

Conclusion

Cancer immunotherapy is entering a more complex and value-driven phase defined by precision biomarkers, advanced biologics, engineered cell therapies, AI-enabled discovery, and regional access differentiation. The sector’s long-term opportunity is supported by rising global cancer incidence and continued clinical progress across both hematologic malignancies and solid tumors.

Sustainable leadership will depend on evidence generation, scalable manufacturing, equitable access, diagnostic readiness, and disciplined access strategies. Organizations that align innovation with measurable patient outcomes, safety management, real-world value, and payer expectations will be best positioned to compete in the evolving global cancer immunotherapy landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.1.1. Expanding Cancer Burden and Treatable Populations
4.3.1.2. Earlier-line and Perioperative Immunotherapy Expansion
4.3.1.3. Broadening Modality and Indication Base
4.3.1.4. Lower-friction Delivery and Access Pathways
4.3.2. Key Restraints
4.3.2.1. Affordability and Evidence Thresholds
4.3.2.2. Complex Treatment Infrastructure and Capacity
4.3.2.3. Response Heterogeneity, Resistance, and Toxicity
4.3.2.4. Uneven Diagnostic and Geographic Access
4.3.3. Key Opportunities
4.3.3.1. Post-checkpoint and Hard-to-treat Disease White Space
4.3.3.2. Subcutaneous and Site-flexible Administration
4.3.3.3. Asia-Pacific Localization and Access Expansion
4.3.3.4. Biomarker-linked Combination and Platform Partnerships
4.3.4. Key Challenges
4.3.4.1. Manufacturing Comparability and Scale-up Control
4.3.4.2. Combination Optimization and Value Attribution
4.3.4.3. Cross-market Regulatory and Reimbursement Sequencing
4.3.4.4. Portfolio Cannibalization and Lifecycle Renewal
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Cancer Immunotherapy Market, by Therapy Class
7.1. Introduction
7.2. Immune Checkpoint Inhibitors
7.3. Tumor-targeting Effector Antibodies
7.4. T-cell Transfer Therapies
7.4.1. CAR T-cell Therapies
7.4.2. Tumor-infiltrating Lymphocyte Therapies
7.4.3. TCR-engineered T-cell Therapies
7.4.4. Antigen-specific T-cell Therapies
7.5. Immune System Modulators
7.5.1. Immunomodulatory Drugs
7.5.2. BCG Immunotherapy
7.5.3. Cytokine Therapies
7.5.3.1. Interleukin Therapies
7.5.3.2. Interferon Therapies
7.6. Immune-cell Engagers
7.6.1. T-cell Engagers
7.6.2. Multi-effector Cell Engagers
7.6.3. Natural Killer Cell Engagers
7.6.4. Myeloid-cell Engagers
7.7. Cancer Treatment Vaccines
7.7.1. Cellular Vaccines
7.7.2. Peptide and Protein Vaccines
7.7.3. Vector-based Vaccines
7.7.4. Nucleic Acid Vaccines
7.8. Costimulatory Receptor Agonist Antibodies
7.9. Gene-delivered Immune Therapies
7.10. Oncolytic Virus Therapies
7.11. Natural Killer Cell Therapies
8. Cancer Immunotherapy Market, by Cancer Type
8.1. Introduction
8.2. Solid Tumors
8.2.1. Thoracic and Mesothelial Cancers
8.2.1.1. Non-Small Cell Lung Cancer
8.2.1.2. Small Cell Lung Cancer
8.2.1.3. Mesothelioma
8.2.1.4. Tracheal, Thymic, and Mediastinal Cancers
8.2.2. Digestive System Cancers
8.2.2.1. Colorectal Cancer
8.2.2.2. Hepatobiliary Cancer
8.2.2.3. Gastric and Gastroesophageal Junction Cancer
8.2.2.4. Pancreatic Cancer
8.2.2.5. Esophageal Cancer
8.2.2.6. Anal Cancer
8.2.2.7. Small Intestinal and Appendiceal Cancers
8.2.3. Genitourinary Cancers
8.2.3.1. Urothelial Tract Cancer
8.2.3.2. Renal Cell Cancer
8.2.3.3. Prostate Cancer
8.2.3.4. Testicular and Penile Cancers
8.2.4. Melanoma
8.2.5. Breast Cancer
8.2.6. Gynecologic Cancers
8.2.6.1. Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
8.2.6.2. Endometrial Cancer
8.2.6.3. Cervical Cancer
8.2.6.4. Vulvar and Vaginal Cancers
8.2.7. Head and Neck Cancers
8.2.8. Nonmelanoma Skin Cancers
8.2.9. Endocrine and Neuroendocrine Cancers
8.2.10. Brain and Central Nervous System Cancers
8.2.11. Bone and Soft Tissue Cancers
8.2.12. Nonmelanoma Ocular Cancers
8.3. Hematologic Malignancies
8.3.1. Plasma Cell Neoplasms
8.3.2. Lymphomas
8.3.3. Leukemias
8.3.4. Myelodysplastic, Myeloproliferative, and Related Neoplasms
9. Cancer Immunotherapy Market, by Indication Scope
9.1. Introduction
9.2. Site- or Histology-defined Indications
9.3. Tumor-agnostic Biomarker-defined Indications
10. Cancer Immunotherapy Market, by Administration Route
10.1. Introduction
10.2. Intravenous
10.3. Subcutaneous
10.4. Oral
10.5. Intravesical
10.6. Intratumoral or Intralesional
10.7. Intramuscular
10.8. Intradermal
10.9. Topical
10.10. Intraperitoneal
11. Cancer Immunotherapy Market, by Cell Therapy Source
11.1. Introduction
11.2. Autologous Cell Therapies
11.3. Allogeneic Cell Therapies
12. Cancer Immunotherapy Market, by Vaccine Antigen Scope
12.1. Introduction
12.2. Shared-antigen Vaccines
12.3. Patient-specific Antigen Vaccines
13. Cancer Immunotherapy Market, by Regimen Configuration
13.1. Introduction
13.2. Single-agent Immunotherapy
13.3. Mixed-modality Combinations
13.4. Immunotherapy-only Combinations
14. Cancer Immunotherapy Market, by Biomarker Selection
14.1. Introduction
14.2. Biomarker-unselected Indications
14.3. Biomarker-selected Indications
15. Cancer Immunotherapy Market, by Cell Therapy Engineering
15.1. Introduction
15.2. Genetically Modified Cell Therapies
15.3. Non-genetically Modified Cell Therapies
16. Cancer Immunotherapy Market, by Region
16.1. Introduction
16.2. North America
16.3. Asia-Pacific
16.4. Europe
16.5. Latin America
16.6. Middle East
16.7. Africa
17. Cancer Immunotherapy Market, by Group
17.1. Introduction
17.2. NATO
17.3. G7
17.4. European Union
17.5. BRICS
17.6. ASEAN
17.7. GCC
18. Cancer Immunotherapy Market, by Country
18.1. Introduction
18.2. United States
18.3. China
18.4. Japan
18.5. Germany
18.6. France
18.7. United Kingdom
18.8. Canada
18.9. South Korea
18.10. Italy
18.11. Australia
18.12. Spain
18.13. India
18.14. Brazil
18.15. Russia
18.16. Mexico
19. Competitive Landscape
19.1. Market Share Analysis, 2025
19.2. Market Concentration Analysis, 2025
19.2.1. Concentration Ratio (CR)
19.2.2. Herfindahl Hirschman Index (HHI)
19.3. Recent Developments & Impact Analysis, 2025
19.4. Product Portfolio Analysis, 2025
19.5. Benchmarking Analysis, 2025
20. Company Profiles
20.1. AbbVie Inc.
20.2. Akeso, Inc.
20.3. Amgen Inc.
20.4. AstraZeneca PLC
20.5. Autolus Therapeutics plc
20.6. BeOne Medicines Ltd.
20.7. BioNTech SE
20.8. Bristol-Myers Squibb Company
20.9. Dendreon
20.10. Ferring Pharmaceuticals A/S
20.11. Genmab A/S
20.12. Gilead Sciences, Inc.
20.13. GSK plc
20.14. ImmunityBio, Inc.
20.15. Innovent Biologics, Inc.
20.16. Iovance Biotherapeutics, Inc.
20.17. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
20.18. Johnson & Johnson
20.19. Legend Biotech Corporation
20.20. Merck & Co., Inc.
20.21. Merck KGaA
20.22. Moderna, Inc.
20.23. Novartis AG
20.24. Pfizer Inc.
20.25. Regeneron Pharmaceuticals, Inc.
20.26. Replimune Group, Inc.
20.27. Roche Holding Ltd.
20.28. Sanofi
20.29. Shanghai Junshi Biosciences Co., Ltd.
21. Key Experts
List of Figures
FIGURE 1. Global Cancer Immunotherapy Market, Years Considered for the Study
FIGURE 2. Global Cancer Immunotherapy Market, Research Design
FIGURE 3. Global Cancer Immunotherapy Market, Research Framework
FIGURE 4. Global Cancer Immunotherapy Market, Data Triangulation
FIGURE 5. Global Cancer Immunotherapy Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Cancer Immunotherapy Market Size, by Therapy Class, 2025 vs 2032 (%)
FIGURE 7. Global Cancer Immunotherapy Market Size, by Therapy Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Cancer Immunotherapy Market Size, by Cancer Type, 2025 vs 2032 (%)
FIGURE 9. Global Cancer Immunotherapy Market Size, by Cancer Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Cancer Immunotherapy Market Size, by Indication Scope, 2025 vs 2032 (%)
FIGURE 11. Global Cancer Immunotherapy Market Size, by Indication Scope, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Cancer Immunotherapy Market Size, by Administration Route, 2025 vs 2032 (%)
FIGURE 13. Global Cancer Immunotherapy Market Size, by Administration Route, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Cancer Immunotherapy Market Size, by Cell Therapy Source, 2025 vs 2032 (%)
FIGURE 15. Global Cancer Immunotherapy Market Size, by Cell Therapy Source, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Cancer Immunotherapy Market Size, by Vaccine Antigen Scope, 2025 vs 2032 (%)
FIGURE 17. Global Cancer Immunotherapy Market Size, by Vaccine Antigen Scope, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Cancer Immunotherapy Market Size, by Regimen Configuration, 2025 vs 2032 (%)
FIGURE 19. Global Cancer Immunotherapy Market Size, by Regimen Configuration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Cancer Immunotherapy Market Size, by Biomarker Selection, 2025 vs 2032 (%)
FIGURE 21. Global Cancer Immunotherapy Market Size, by Biomarker Selection, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 22. Global Cancer Immunotherapy Market Size, by Cell Therapy Engineering, 2025 vs 2032 (%)
FIGURE 23. Global Cancer Immunotherapy Market Size, by Cell Therapy Engineering, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 24. Global Cancer Immunotherapy Market Size, by Region, 2025 vs 2032 (%)
FIGURE 25. Global Cancer Immunotherapy Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 26. Global Cancer Immunotherapy Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 27. Global Cancer Immunotherapy Market Size, by Country, 2025 vs 2032 (%)
FIGURE 28. Global Cancer Immunotherapy Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 29. Global Cancer Immunotherapy Market Share, by Key Player, 2025
List of Tables
TABLE 1. Global Cancer Immunotherapy Market Segmentation & Coverage
TABLE 2. Global Cancer Immunotherapy Market Size, 2017-2032 (USD Million)
TABLE 3. Global Cancer Immunotherapy Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 4. Global Immune Checkpoint Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Immune Checkpoint Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Immune Checkpoint Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Tumor-targeting Effector Antibodies Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Tumor-targeting Effector Antibodies Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Tumor-targeting Effector Antibodies Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global T-cell Transfer Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global T-cell Transfer Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global T-cell Transfer Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global CAR T-cell Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global CAR T-cell Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global CAR T-cell Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Tumor-infiltrating Lymphocyte Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Tumor-infiltrating Lymphocyte Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Tumor-infiltrating Lymphocyte Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global TCR-engineered T-cell Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global TCR-engineered T-cell Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global TCR-engineered T-cell Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Antigen-specific T-cell Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Antigen-specific T-cell Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Antigen-specific T-cell Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Immune System Modulators Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Immune System Modulators Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Immune System Modulators Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Immunomodulatory Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Immunomodulatory Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Immunomodulatory Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global BCG Immunotherapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global BCG Immunotherapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global BCG Immunotherapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Cytokine Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Cytokine Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Cytokine Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Interleukin Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Interleukin Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Interleukin Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Interferon Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Interferon Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Interferon Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Immune-cell Engagers Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Immune-cell Engagers Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Immune-cell Engagers Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global T-cell Engagers Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global T-cell Engagers Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global T-cell Engagers Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Multi-effector Cell Engagers Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Multi-effector Cell Engagers Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Multi-effector Cell Engagers Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Natural Killer Cell Engagers Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Natural Killer Cell Engagers Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Natural Killer Cell Engagers Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Myeloid-cell Engagers Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Myeloid-cell Engagers Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Myeloid-cell Engagers Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Cancer Treatment Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Cancer Treatment Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Cancer Treatment Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Cellular Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Cellular Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Cellular Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Peptide and Protein Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Peptide and Protein Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Peptide and Protein Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Vector-based Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Vector-based Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Vector-based Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Nucleic Acid Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global Nucleic Acid Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global Nucleic Acid Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global Costimulatory Receptor Agonist Antibodies Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Global Costimulatory Receptor Agonist Antibodies Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. Global Costimulatory Receptor Agonist Antibodies Market Size, by Country, 2017-2032 (USD Million)
TABLE 76. Global Gene-delivered Immune Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Global Gene-delivered Immune Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. Global Gene-delivered Immune Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 79. Global Oncolytic Virus Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Global Oncolytic Virus Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 81. Global Oncolytic Virus Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 82. Global Natural Killer Cell Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Global Natural Killer Cell Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 84. Global Natural Killer Cell Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 85. Global Cancer Immunotherapy Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 86. Global Solid Tumors Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. Global Solid Tumors Market Size, by Group, 2017-2032 (USD Million)
TABLE 88. Global Solid Tumors Market Size, by Country, 2017-2032 (USD Million)
TABLE 89. Global Thoracic and Mesothelial Cancers Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Global Thoracic and Mesothelial Cancers Market Size, by Group, 2017-2032 (USD Million)
TABLE 91. Global Thoracic and Mesothelial Cancers Market Size, by Country, 2017-2032 (USD Million)
TABLE 92. Global Non-Small Cell Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 93. Global Non-Small Cell Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 94. Global Non-Small Cell Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 95. Global Small Cell Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 96. Global Small Cell Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 97. Global Small Cell Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 98. Global Mesothelioma Market Size, by Region, 2017-2032 (USD Million)
TABLE 99. Global Mesothelioma Market Size, by Group, 2017-2032 (USD Million)
TABLE 100. Global Mesothelioma Market Size, by Country, 2017-2032 (USD Million)
TABLE 101. Global Tracheal, Thymic, and Mediastinal Cancers Market Size, by Region, 2017-2032 (USD Million)
TABLE 102. Global Tracheal, Thymic, and Mediastinal Cancers Market Size, by Group, 2017-2032 (USD Million)
TABLE 103. Global Tracheal, Thymic, and Mediastinal Cancers Market Size, by Country, 2017-2032 (USD Million)
TABLE 104. Global Digestive System Cancers Market Size, by Region, 2017-2032 (USD Million)
TABLE 105. Global Digestive System Cancers Market Size, by Group, 2017-2032 (USD Million)
TABLE 106. Global Digestive System Cancers Market Size, by Country, 2017-2032 (USD Million)
TABLE 107. Global Colorectal Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 108. Global Colorectal Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 109. Global Colorectal Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 110. Global Hepatobiliary Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 111. Global Hepatobiliary Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 112. Global Hepatobiliary Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 113. Global Gastric and Gastroesophageal Junction Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 114. Global Gastric and Gastroesophageal Junction Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 115. Global Gastric and Gastroesophageal Junction Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 116. Global Pancreatic Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 117. Global Pancreatic Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 118. Global Pancreatic Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 119. Global Esophageal Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 120. Global Esophageal Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 121. Global Esophageal Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 122. Global Anal Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 123. Global Anal Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 124. Global Anal Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 125. Global Small Intestinal and Appendiceal Cancers Market Size, by Region, 2017-2032 (USD Million)
TABLE 126. Global Small Intestinal and Appendiceal Cancers Market Size, by Group, 2017-2032 (USD Million)
TABLE 127. Global Small Intestinal and Appendiceal Cancers Market Size, by Country, 2017-2032 (USD Million)
TABLE 128. Global Genitourinary Cancers Market Size, by Region, 2017-2032 (USD Million)
TABLE 129. Global Genitourinary Cancers Market Size, by Group, 2017-2032 (USD Million)
TABLE 130. Global Genitourinary Cancers Market Size, by Country, 2017-2032 (USD Million)
TABLE 131. Global Urothelial Tract Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 132. Global Urothelial Tract Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 133. Global Urothelial Tract Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 134. Global Renal Cell Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 135. Global Renal Cell Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 136. Global Renal Cell Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 137. Global Prostate Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 138. Global Prostate Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 139. Global Prostate Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 140. Global Testicular and Penile Cancers Market Size, by Region, 2017-2032 (USD Million)
TABLE 141. Global Testicular and Penile Cancers Market Size, by Group, 2017-2032 (USD Million)
TABLE 142. Global Testicular and Penile Cancers Market Size, by Country, 2017-2032 (USD Million)
TABLE 143. Global Melanoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 144. Global Melanoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 145. Global Melanoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 146. Global Breast Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 147. Global Breast Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 148. Global Breast Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 149. Global Gynecologic Cancers Market Size, by Region, 2017-2032 (USD Million)
TABLE 150. Global Gynecologic Cancers Market Size, by Group, 2017-2032 (USD Million)
TABLE 151. Global Gynecologic Cancers Market Size, by Country, 2017-2032 (USD Million)
TABLE 152. Global Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 153. Global Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 154. Global Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 155. Global Endometrial Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 156. Global Endometrial Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 157. Global Endometrial Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 158. Global Cervical Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 159. Global Cervical Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 160. Global Cervical Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 161. Global Vulvar and Vaginal Cancers Market Size, by Region, 2017-2032 (USD Million)
TABLE 162. Global Vulvar and Vaginal Cancers Market Size, by Group, 2017-2032 (USD Million)
TABLE 163. Global Vulvar and Vaginal Cancers Market Size, by Country, 2017-2032 (USD Million)
TABLE 164. Global Head and Neck Cancers Market Size, by Region, 2017-2032 (USD Million)
TABLE 165. Global Head and Neck Cancers Market Size, by Group, 2017-2032 (USD Million)
TABLE 166. Global Head and Neck Cancers Market Size, by Country, 2017-2032 (USD Million)
TABLE 167. Global Nonmelanoma Skin Cancers Market Size, by Region, 2017-2032 (USD Million)
TABLE 168. Global Nonmelanoma Skin Cancers Market Size, by Group, 2017-2032 (USD Million)
TABLE 169. Global Nonmelanoma Skin Cancers Market Size, by Country, 2017-2032 (USD Million)
TABLE 170. Global Endocrine and Neuroendocrine Cancers Market Size, by Region, 2017-2032 (USD Million)
TABLE 171. Global Endocrine and Neuroendocrine Cancers Market Size, by Group, 2017-2032 (USD Million)
TABLE 172. Global Endocrine and Neuroendocrine Cancers Market Size, by Country, 2017-2032 (USD Million)
TABLE 173. Global Brain and Central Nervous System Cancers Market Size, by Region, 2017-2032 (USD Million)
TABLE 174. Global Brain and Central Nervous System Cancers Market Size, by Group, 2017-2032 (USD Million)
TABLE 175. Global Brain and Central Nervous System Cancers Market Size, by Country, 2017-2032 (USD Million)
TABLE 176. Global Bone and Soft Tissue Cancers Market Size, by Region, 2017-2032 (USD Million)
TABLE 177. Global Bone and Soft Tissue Cancers Market Size, by Group, 2017-2032 (USD Million)
TABLE 178. Global Bone and Soft Tissue Cancers Market Size, by Country, 2017-2032 (USD Million)
TABLE 179. Global Nonmelanoma Ocular Cancers Market Size, by Region, 2017-2032 (USD Million)
TABLE 180. Global Nonmelanoma Ocular Cancers Market Size, by Group, 2017-2032 (USD Million)
TABLE 181. Global Nonmelanoma Ocular Cancers Market Size, by Country, 2017-2032 (USD Million)
TABLE 182. Global Hematologic Malignancies Market Size, by Region, 2017-2032 (USD Million)
TABLE 183. Global Hematologic Malignancies Market Size, by Group, 2017-2032 (USD Million)
TABLE 184. Global Hematologic Malignancies Market Size, by Country, 2017-2032 (USD Million)
TABLE 185. Global Plasma Cell Neoplasms Market Size, by Region, 2017-2032 (USD Million)
TABLE 186. Global Plasma Cell Neoplasms Market Size, by Group, 2017-2032 (USD Million)
TABLE 187. Global Plasma Cell Neoplasms Market Size, by Country, 2017-2032 (USD Million)
TABLE 188. Global Lymphomas Market Size, by Region, 2017-2032 (USD Million)
TABLE 189. Global Lymphomas Market Size, by Group, 2017-2032 (USD Million)
TABLE 190. Global Lymphomas Market Size, by Country, 2017-2032 (USD Million)
TABLE 191. Global Leukemias Market Size, by Region, 2017-2032 (USD Million)
TABLE 192. Global Leukemias Market Size, by Group, 2017-2032 (USD Million)
TABLE 193. Global Leukemias Market Size, by Country, 2017-2032 (USD Million)
TABLE 194. Global Myelodysplastic, Myeloproliferative, and Related Neoplasms Market Size, by Region, 2017-2032 (USD Million)
TABLE 195. Global Myelodysplastic, Myeloproliferative, and Related Neoplasms Market Size, by Group, 2017-2032 (USD Million)
TABLE 196. Global Myelodysplastic, Myeloproliferative, and Related Neoplasms Market Size, by Country, 2017-2032 (USD Million)
TABLE 197. Global Cancer Immunotherapy Market Size, by Indication Scope, 2017-2032 (USD Million)
TABLE 198. Global Site- or Histology-defined Indications Market Size, by Region, 2017-2032 (USD Million)
TABLE 199. Global Site- or Histology-defined Indications Market Size, by Group, 2017-2032 (USD Million)
TABLE 200. Global Site- or Histology-defined Indications Market Size, by Country, 2017-2032 (USD Million)
TABLE 201. Global Tumor-agnostic Biomarker-defined Indications Market Size, by Region, 2017-2032 (USD Million)
TABLE 202. Global Tumor-agnostic Biomarker-defined Indications Market Size, by Group, 2017-2032 (USD Million)
TABLE 203. Global Tumor-agnostic Biomarker-defined Indications Market Size, by Country, 2017-2032 (USD Million)
TABLE 204. Global Cancer Immunotherapy Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 205. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 206. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 207. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 208. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 209. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 210. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 211. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 212. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 213. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 214. Global Intravesical Market Size, by Region, 2017-2032 (USD Million)
TABLE 215. Global Intravesical Market Size, by Group, 2017-2032 (USD Million)
TABLE 216. Global Intravesical Market Size, by Country, 2017-2032 (USD Million)
TABLE 217. Global Intratumoral or Intralesional Market Size, by Region, 2017-2032 (USD Million)
TABLE 218. Global Intratumoral or Intralesional Market Size, by Group, 2017-2032 (USD Million)
TABLE 219. Global Intratumoral or Intralesional Market Size, by Country, 2017-2032 (USD Million)
TABLE 220. Global Intramuscular Market Size, by Region, 2017-2032 (USD Million)
TABLE 221. Global Intramuscular Market Size, by Group, 2017-2032 (USD Million)
TABLE 222. Global Intramuscular Market Size, by Country, 2017-2032 (USD Million)
TABLE 223. Global Intradermal Market Size, by Region, 2017-2032 (USD Million)
TABLE 224. Global Intradermal Market Size, by Group, 2017-2032 (USD Million)
TABLE 225. Global Intradermal Market Size, by Country, 2017-2032 (USD Million)
TABLE 226. Global Topical Market Size, by Region, 2017-2032 (USD Million)
TABLE 227. Global Topical Market Size, by Group, 2017-2032 (USD Million)
TABLE 228. Global Topical Market Size, by Country, 2017-2032 (USD Million)
TABLE 229. Global Intraperitoneal Market Size, by Region, 2017-2032 (USD Million)
TABLE 230. Global Intraperitoneal Market Size, by Group, 2017-2032 (USD Million)
TABLE 231. Global Intraperitoneal Market Size, by Country, 2017-2032 (USD Million)
TABLE 232. Global Cancer Immunotherapy Market Size, by Cell Therapy Source, 2017-2032 (USD Million)
TABLE 233. Global Autologous Cell Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 234. Global Autologous Cell Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 235. Global Autologous Cell Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 236. Global Allogeneic Cell Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 237. Global Allogeneic Cell Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 238. Global Allogeneic Cell Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 239. Global Cancer Immunotherapy Market Size, by Vaccine Antigen Scope, 2017-2032 (USD Million)
TABLE 240. Global Shared-antigen Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 241. Global Shared-antigen Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 242. Global Shared-antigen Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 243. Global Patient-specific Antigen Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 244. Global Patient-specific Antigen Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 245. Global Patient-specific Antigen Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 246. Global Cancer Immunotherapy Market Size, by Regimen Configuration, 2017-2032 (USD Million)
TABLE 247. Global Single-agent Immunotherapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 248. Global Single-agent Immunotherapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 249. Global Single-agent Immunotherapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 250. Global Mixed-modality Combinations Market Size, by Region, 2017-2032 (USD Million)
TABLE 251. Global Mixed-modality Combinations Market Size, by Group, 2017-2032 (USD Million)
TABLE 252. Global Mixed-modality Combinations Market Size, by Country, 2017-2032 (USD Million)
TABLE 253. Global Immunotherapy-only Combinations Market Size, by Region, 2017-2032 (USD Million)
TABLE 254. Global Immunotherapy-only Combinations Market Size, by Group, 2017-2032 (USD Million)
TABLE 255. Global Immunotherapy-only Combinations Market Size, by Country, 2017-2032 (USD Million)
TABLE 256. Global Cancer Immunotherapy Market Size, by Biomarker Selection, 2017-2032 (USD Million)
TABLE 257. Global Biomarker-unselected Indications Market Size, by Region, 2017-2032 (USD Million)
TABLE 258. Global Biomarker-unselected Indications Market Size, by Group, 2017-2032 (USD Million)
TABLE 259. Global Biomarker-unselected Indications Market Size, by Country, 2017-2032 (USD Million)
TABLE 260. Global Biomarker-selected Indications Market Size, by Region, 2017-2032 (USD Million)
TABLE 261. Global Biomarker-selected Indications Market Size, by Group, 2017-2032 (USD Million)
TABLE 262. Global Biomarker-selected Indications Market Size, by Country, 2017-2032 (USD Million)
TABLE 263. Global Cancer Immunotherapy Market Size, by Cell Therapy Engineering, 2017-2032 (USD Million)
TABLE 264. Global Genetically Modified Cell Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 265. Global Genetically Modified Cell Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 266. Global Genetically Modified Cell Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 267. Global Non-genetically Modified Cell Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 268. Global Non-genetically Modified Cell Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 269. Global Non-genetically Modified Cell Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 270. Global Cancer Immunotherapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 271. North America Cancer Immunotherapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 272. North America Cancer Immunotherapy Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 273. North America Cancer Immunotherapy Market Size, by T-cell Transfer Therapies, 2017-2032 (USD Million)
TABLE 274. North America Cancer Immunotherapy Market Size, by Immune System Modulators, 2017-2032 (USD Million)
TABLE 275. North America Cancer Immunotherapy Market Size, by Cytokine Therapies, 2017-2032 (USD Million)
TABLE 276. North America Cancer Immunotherapy Market Size, by Immune-cell Engagers, 2017-2032 (USD Million)
TABLE 277. North America Cancer Immunotherapy Market Size, by Cancer Treatment Vaccines, 2017-2032 (USD Million)
TABLE 278. North America Cancer Immunotherapy Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 279. North America Cancer Immunotherapy Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 280. North America Cancer Immunotherapy Market Size, by Thoracic and Mesothelial Cancers, 2017-2032 (USD Million)
TABLE 281. North America Cancer Immunotherapy Market Size, by Digestive System Cancers, 2017-2032 (USD Million)
TABLE 282. North America Cancer Immunotherapy Market Size, by Genitourinary Cancers, 2017-2032 (USD Million)
TABLE 283. North America Cancer Immunotherapy Market Size, by Gynecologic Cancers, 2017-2032 (USD Million)
TABLE 284. North America Cancer Immunotherapy Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
TABLE 285. North America Cancer Immunotherapy Market Size, by Indication Scope, 2017-2032 (USD Million)
TABLE 286. North America Cancer Immunotherapy Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 287. North America Cancer Immunotherapy Market Size, by Cell Therapy Source, 2017-2032 (USD Million)
TABLE 288. North America Cancer Immunotherapy Market Size, by Vaccine Antigen Scope, 2017-2032 (USD Million)
TABLE 289. North America Cancer Immunotherapy Market Size, by Regimen Configuration, 2017-2032 (USD Million)
TABLE 290. North America Cancer Immunotherapy Market Size, by Biomarker Selection, 2017-2032 (USD Million)
TABLE 291. North America Cancer Immunotherapy Market Size, by Cell Therapy Engineering, 2017-2032 (USD Million)
TABLE 292. Asia-Pacific Cancer Immunotherapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 293. Asia-Pacific Cancer Immunotherapy Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 294. Asia-Pacific Cancer Immunotherapy Market Size, by T-cell Transfer Therapies, 2017-2032 (USD Million)
TABLE 295. Asia-Pacific Cancer Immunotherapy Market Size, by Immune System Modulators, 2017-2032 (USD Million)
TABLE 296. Asia-Pacific Cancer Immunotherapy Market Size, by Cytokine Therapies, 2017-2032 (USD Million)
TABLE 297. Asia-Pacific Cancer Immunotherapy Market Size, by Immune-cell Engagers, 2017-2032 (USD Million)
TABLE 298. Asia-Pacific Cancer Immunotherapy Market Size, by Cancer Treatment Vaccines, 2017-2032 (USD Million)
TABLE 299. Asia-Pacific Cancer Immunotherapy Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 300. Asia-Pacific Cancer Immunotherapy Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 301. Asia-Pacific Cancer Immunotherapy Market Size, by Thoracic and Mesothelial Cancers, 2017-2032 (USD Million)
TABLE 302. Asia-Pacific Cancer Immunotherapy Market Size, by Digestive System Cancers, 2017-2032 (USD Million)
TABLE 303. Asia-Pacific Cancer Immunotherapy Market Size, by Genitourinary Cancers, 2017-2032 (USD Million)
TABLE 304. Asia-Pacific Cancer Immunotherapy Market Size, by Gynecologic Cancers, 2017-2032 (USD Million)
TABLE 305. Asia-Pacific Cancer Immunotherapy Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
TABLE 306. Asia-Pacific Cancer Immunotherapy Market Size, by Indication Scope, 2017-2032 (USD Million)
TABLE 307. Asia-Pacific Cancer Immunotherapy Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 308. Asia-Pacific Cancer Immunotherapy Market Size, by Cell Therapy Source, 2017-2032 (USD Million)
TABLE 309. Asia-Pacific Cancer Immunotherapy Market Size, by Vaccine Antigen Scope, 2017-2032 (USD Million)
TABLE 310. Asia-Pacific Cancer Immunotherapy Market Size, by Regimen Configuration, 2017-2032 (USD Million)
TABLE 311. Asia-Pacific Cancer Immunotherapy Market Size, by Biomarker Selection, 2017-2032 (USD Million)
TABLE 312. Asia-Pacific Cancer Immunotherapy Market Size, by Cell Therapy Engineering, 2017-2032 (USD Million)
TABLE 313. Europe Cancer Immunotherapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 314. Europe Cancer Immunotherapy Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 315. Europe Cancer Immunotherapy Market Size, by T-cell Transfer Therapies, 2017-2032 (USD Million)
TABLE 316. Europe Cancer Immunotherapy Market Size, by Immune System Modulators, 2017-2032 (USD Million)
TABLE 317. Europe Cancer Immunotherapy Market Size, by Cytokine Therapies, 2017-2032 (USD Million)
TABLE 318. Europe Cancer Immunotherapy Market Size, by Immune-cell Engagers, 2017-2032 (USD Million)
TABLE 319. Europe Cancer Immunotherapy Market Size, by Cancer Treatment Vaccines, 2017-2032 (USD Million)
TABLE 320. Europe Cancer Immunotherapy Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 321. Europe Cancer Immunotherapy Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 322. Europe Cancer Immunotherapy Market Size, by Thoracic and Mesothelial Cancers, 2017-2032 (USD Million)
TABLE 323. Europe Cancer Immunotherapy Market Size, by Digestive System Cancers, 2017-2032 (USD Million)
TABLE 324. Europe Cancer Immunotherapy Market Size, by Genitourinary Cancers, 2017-2032 (USD Million)
TABLE 325. Europe Cancer Immunotherapy Market Size, by Gynecologic Cancers, 2017-2032 (USD Million)
TABLE 326. Europe Cancer Immunotherapy Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
TABLE 327. Europe Cancer Immunotherapy Market Size, by Indication Scope, 2017-2032 (USD Million)
TABLE 328. Europe Cancer Immunotherapy Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 329. Europe Cancer Immunotherapy Market Size, by Cell Therapy Source, 2017-2032 (USD Million)
TABLE 330. Europe Cancer Immunotherapy Market Size, by Vaccine Antigen Scope, 2017-2032 (USD Million)
TABLE 331. Europe Cancer Immunotherapy Market Size, by Regimen Configuration, 2017-2032 (USD Million)
TABLE 332. Europe Cancer Immunotherapy Market Size, by Biomarker Selection, 2017-2032 (USD Million)
TABLE 333. Europe Cancer Immunotherapy Market Size, by Cell Therapy Engineering, 2017-2032 (USD Million)
TABLE 334. Latin America Cancer Immunotherapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 335. Latin America Cancer Immunotherapy Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 336. Latin America Cancer Immunotherapy Market Size, by T-cell Transfer Therapies, 2017-2032 (USD Million)
TABLE 337. Latin America Cancer Immunotherapy Market Size, by Immune System Modulators, 2017-2032 (USD Million)
TABLE 338. Latin America Cancer Immunotherapy Market Size, by Cytokine Therapies, 2017-2032 (USD Million)
TABLE 339. Latin America Cancer Immunotherapy Market Size, by Immune-cell Engagers, 2017-2032 (USD Million)
TABLE 340. Latin America Cancer Immunotherapy Market Size, by Cancer Treatment Vaccines, 2017-2032 (USD Million)
TABLE 341. Latin America Cancer Immunotherapy Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 342. Latin America Cancer Immunotherapy Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 343. Latin America Cancer Immunotherapy Market Size, by Thoracic and Mesothelial Cancers, 2017-2032 (USD Million)
TABLE 344. Latin America Cancer Immunotherapy Market Size, by Digestive System Cancers, 2017-2032 (USD Million)
TABLE 345. Latin America Cancer Immunotherapy Market Size, by Genitourinary Cancers, 2017-2032 (USD Million)
TABLE 346. Latin America Cancer Immunotherapy Market Size, by Gynecologic Cancers, 2017-2032 (USD Million)
TABLE 347. Latin America Cancer Immunotherapy Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
TABLE 348. Latin America Cancer Immunotherapy Market Si

Companies Mentioned

  • AbbVie Inc.
  • Akeso, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Autolus Therapeutics plc
  • BeOne Medicines Ltd.
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • Dendreon
  • Ferring Pharmaceuticals A/S
  • Genmab A/S
  • Gilead Sciences, Inc.
  • GSK plc
  • ImmunityBio, Inc.
  • Innovent Biologics, Inc.
  • Iovance Biotherapeutics, Inc.
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • Johnson & Johnson
  • Legend Biotech Corporation
  • Merck & Co., Inc.
  • Merck KGaA
  • Moderna, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Replimune Group, Inc.
  • Roche Holding Ltd.
  • Sanofi
  • Shanghai Junshi Biosciences Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages193
PublishedSeptember 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 162.78 Billion
Forecasted Market Value ( USD ) by 2032 $ 293.07 Billion
Compound Annual Growth Rate10.7%
Regions CoveredGlobal
No. of Companies Mentioned29

Related Topics

Related Reports

Cancer Immunotherapy Drugs Market - Global Forecast 2026-2032 - Product Image

Cancer Immunotherapy Drugs Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
Cancer Immunotherapy Drug Discovery Outsourcing Market - Global Forecast 2026-2032 - Product Image

Cancer Immunotherapy Drug Discovery Outsourcing Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Cancer Immunotherapy - Global Strategic Business Report - Product Image

Cancer Immunotherapy - Global Strategic Business Report

  • Report
  • 291 Pages
  • Global
From
Oncolytic Virus Immunotherapy Market Opportunity, Technology Platforms, Approved Therapy Dosage, Price & Clinical Trials Insight 2031 - Product Image

Oncolytic Virus Immunotherapy Market Opportunity, Technology Platforms, Approved Therapy Dosage, Price & Clinical Trials Insight 2031

  • Report
  • 410 Pages
  • Global
From
Cellular Immunotherapy - Global Strategic Business Report - Product Image

Cellular Immunotherapy - Global Strategic Business Report

  • Report
  • 386 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.